Supplementary Figure 1. [ 18 F]FHBG is not retained, phosphorylated, or incorporated into the DNA of B16 cells. (A-C) For the in vitro studies a panel.

Slides:

Advertisements

Similar presentations

Supplementary Figure S1. Hematoxylin and eosin (H&E) staining (left panel) and ASP+ fluorescence labeling (right panel) of adjacent sections containing.

Advertisements

Supplemental Figure 1 A B Supplemental Figure 1. F ‑ IgG and IL-12 mediated NK cell lysis is dependent on the folate receptor availability and does not.

Figure 1. Herbacetin binds to AKT1/2 and suppresses each respective kinase activity. The effect of herbacetin on (A) PI3K/AKT and (B) MAPK signaling pathway.

Tumor-Induced Sentinel Lymph Node Lymphangiogenesis and Increased Lymph Flow Precede Melanoma Metastasis Maria I. Harrell, Brian M. Iritani, Alanna Ruddell

Figure 1. Herbacetin binds to AKT1/2 and suppresses each respective kinase activity. The effect of herbacetin on (A) PI3K/AKT and (B) MAPK signaling pathway.

Antitumor effect of the combination of IL-2 IC and anti–CTLA-4.

Volume 14, Issue 6, Pages (December 2011)

Cheng-Ming Sun, Edith Deriaud, Claude Leclerc, Richard Lo-Man Immunity

Volume 19, Issue 1, Pages (July 2003)

In vivo gene transfer of pigment epithelium-derived factor inhibits tumor growth in syngeneic murine models of thoracic malignancies Ali Mahtabifard,

The biodistribution and pharmacokinetics of [68Ga]Ga-1 in the orthotopic xenograft mice using µPET dynamic acquisitions. The biodistribution and pharmacokinetics.

T Cell-Activating Mesenchymal Stem Cells as a Biotherapeutic for HCC

In vivo imaging of molecular-genetic targets for cancer therapy

Intratumoral Immunization by p19Arf and Interferon-β Gene Transfer in a Heterotopic Mouse Model of Lung Carcinoma João Paulo Portela Catani, Ruan F.V.

Figure S1A. Supplementary Figure S1A. In vitro infectivity of vaccinia virus after exposure to cavitation. A dose of 1x106 vaccinia virus was mixed with.

Volume 26, Issue 3, Pages (March 2007)

Volume 31, Issue 1, Pages (July 2009)

Volume 142, Issue 4, Pages (August 2010)

In Vivo Imaging of Inflammatory Phagocytes

Volume 16, Issue 11, Pages (September 2016)

In the Hunt for Therapeutic Targets: Mimicking the Growth, Metastasis, and Stromal Associations of Early-Stage Lung Cancer Using a Novel Orthotopic Animal.

Tumor risk by tissue engineering: cartilaginous differentiation of mesenchymal stem cells reduces tumor growth I. Akay, D. Oxmann, A. Helfenstein, R.

Targeting an Oncolytic Influenza A Virus to Tumor Tissue by Elastase

Volume 41, Issue 5, Pages (November 2014)

Volume 13, Issue 1, Pages (January 2006)

Volume 36, Issue 3, Pages (March 2012)

Quantitative PET Reporter Gene Imaging with [11C]Trimethoprim

Volume 10, Issue 9, Pages (March 2015)

Volume 22, Issue 1, Pages (July 2012)

Matthew P. Pando, David Morse, Nicolas Cermakian, Paolo Sassone-Corsi

Pharmacodynamic effects of PI3K inhibitor NVP-BKM120 on breast carcinomas in MMTV-CreBrca1f/fTrp53+/− mice. Pharmacodynamic effects of PI3K inhibitor NVP-BKM120.

Volume 25, Issue 1, Pages (January 2017)

Jin-Sung Chung, Kyoichi Tamura, Ponciano D. Cruz, Kiyoshi Ariizumi

Modeling the Therapeutic Efficacy of p53 Restoration in Tumors

Volume 14, Issue 8, Pages (March 2016)

Volume 5, Issue 6, Pages (December 2015)

Volume 29, Issue 6, Pages (December 2008)

Effect of plumbagin (PL) on the growth of prostate tumors in Pten-KO mice. Effect of plumbagin (PL) on the growth of prostate tumors in Pten-KO mice. A.

Myeloma cell–derived Runx2 promotes myeloma progression in bone

Volume 20, Issue 13, Pages (September 2017)

Volume 25, Issue 7, Pages (July 2017)

Volume 23, Issue 4, Pages (April 2015)

Volume 23, Issue 4, Pages (April 2015)

Exosomes from M1-Polarized Macrophages Potentiate the Cancer Vaccine by Creating a Pro-inflammatory Microenvironment in the Lymph Node Lifang Cheng,

Volume 6, Issue 4, Pages (October 2004)

by Derek Hoi-Hang Ho, and Roger Hoi-Fung Wong

CD301b+ Dermal Dendritic Cells Drive T Helper 2 Cell-Mediated Immunity

Fig. 2 In vitro and preclinical study with 18F-MPG.

Volume 44, Issue 4, Pages (April 2016)

Chie Kudo-Saito, Hiromi Shirako, Tadashi Takeuchi, Yutaka Kawakami

Volume 24, Issue 1, Pages (January 2016)

Karen Laky, Sharron Evans, Ainhoa Perez-Diez, B.J. Fowlkes Immunity

Macrophage Inhibitory Cytokine-1 Is Overexpressed in Malignant Melanoma and Is Associated with Tumorigenicity Glen M. Boyle, Julie Pedley, Adam C. Martyn,

Elimination of CD4+ T Cells Enhances Anti-Tumor Effect of Locally Secreted Interleukin- 12 on B16 Mouse Melanoma and Induces Vitiligo-Like Coat Color Alteration

Volume 22, Issue 1, Pages (July 2012)

Serial vaccination with 32Dp210-derived whole cell vaccines in non-tumor-bearing mice stimulates robust antileukemic cytolytic activity. Serial vaccination.

Volume 33, Issue 6, Pages (December 2010)

MicroPET and CCD imaging of β-cells in MIP-TF mice.

Abhijit De, Xiaoman Zhou Lewis, Sanjiv Sam Gambhir Molecular Therapy

MRNA Vaccine with Antigen-Specific Checkpoint Blockade Induces an Enhanced Immune Response against Established Melanoma Yuhua Wang, Lu Zhang, Zhenghong.

Supplementary figure 1 A B Water (Control) Pre-alcohol Post-alcohol

Gemcitabine-Incorporated G-Quadruplex Aptamer for Targeted Drug Delivery into Pancreas Cancer Jun Young Park, Ye Lim Cho, Ju Ri Chae, Sung Hwan Moon,

PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination. PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination.

Fig. 2 In vitro and preclinical study with 18F-MPG.

Collapse of the Tumor Stroma is Triggered by IL-12 Induction of Fas

Model of minimal residual disease.

Increased accumulation of pmel-1 T cells to tumor sites and enhanced antitumor immune response in mice receiving ACT combined with anti-PD-1 antibody treatment.

In vivo tumor targeting and biodistribution of radiolabeled anti-CEA Fab-H-2Kb/ova conjugates. In vivo tumor targeting and biodistribution of radiolabeled.

MET activation confers resistance to cetuximab (Cmab) or panitumumab (Pmab) in colon cancer cell lines in vitro and in vivo. MET activation confers resistance.

Volume 2, Issue 6, Pages (December 2012)

Presentation transcript:

Supplementary Figure 1. [ 18 F]FHBG is not retained, phosphorylated, or incorporated into the DNA of B16 cells. (A-C) For the in vitro studies a panel of cell lines was used: B16 melanoma cells, BaF3 wt and BaF3 with sr39tk over-expressed, primary activated pmel T-cells and activated pmel cells transduced with sr39tk. (D-F) For the in vivo studies B16 and BaF3- sr39tk cells were subcutaneously injected into mice 1 week prior to i.v. injection of [ 18 F]FHBG. After a 1hr uptake, mice were sacrificed and tumors were harvested. The following measurements were made: (A, D) amount of [ 18 F]FHBG retained in cells, (B, E) amount of [ 18 F]FHBG phosphorylated, (C, F) amount of [ 18 F]FHBG incorporated in DNA after 4hr. A.D. B. C. E. F.

Day 1 Day 3 Day 5 Day 8 Day %ID/g Day 12 Day 15 Day 17 Day 19 Day %ID/g Day 1 Day 3 Day 5 Day 8 Day %ID/g Day 12 Day 15 Day 17 Day 19 Day %ID/g Day 1 Day 3 Day 5 Day 8 Day %ID/g Day 12 Day 15 Day 17 Day 19 Day %ID/g T TT TTTTT TTT TTT T TTTT TTTT BB B B B B B B B BB B B B A B A A B B AA A A A A C C C C Mouse 1 Mouse 2 Mouse 3 C C C B B A

Day 1 Day 3 Day 5 Day 8 Day %ID/g Day 12 Day 15 Day 17 Day 19 Day %ID/g Day 1 Day 3 Day 5 Day 8 Day %ID/g Day 12 Day 15 Day 17 Day 19 Day %ID/g Day 12 Day 15 Day 17 Day 19 Day %ID/g B B T T T T T T T TT T T T T A A A A A B B B B B T TT TT T T A B B Mouse 5 Mouse 6 Mouse 4 Day 1 Day 3 Day 5 Day 8 Day %ID/g B B T T T B B B CC C

Mouse 7 Day 1 Day 3 Day 5 Day 8 Day %ID/g B B B B T B T Day 12 Day 15 Day 17 Day 19 Day %ID/g TT T T B Supplementary Figure 2. Longitudinal changes in T cell trafficking. Seven mice were imaged with microPET/CT 60 min after i.v. injection with [ 18 F]FHBG. Representative 3-D microPET/CT images of the same mouse on different days are displayed. Red arrows indicate days that mice received gp /DC vaccine and high dose IL-2. A, axillary LN; B, brachial LN; C, cervical LN; T, tumor

Supplementary Figure 3. Detection of sr39tk + T-cells over the nonspecific accumulation of [ 18 F]FHBG in B16 tumors. (A) C57BL/6 mice were implanted s.c. with 1 x 10 5 B16 cells in the right shoulder on day 1. Mice with tumors >1cm in diameter were imaged with [ 18 F]FHBG microPET/CT on day 8. Immediately after imaging, 5x10 6 sr39tk+ T-cells were injected intra- tumorally. After 30 min, a second dose of [ 18 F]FHBG was injected i.v.. Following a 1hr uptake of the probe mice were again imaged by microPET/CT. (B) Representative 3-D microPET/CT images of three mice with B16 tumors alone (left panels) and the same B16 tumors with sr39tk+ T-cells (right panels). T, tumor. (C) Quantitation of [ 18 F]FHBG in B16 tumors alone and the same B16 tumors with sr39tk+ T-cells. A. B %ID/g %ID/g Mouse #1 Mouse #2 Mouse #3 B16 alone B16 + sr39tk + T-cell B16 melanoma bearing mouse [ 18 F]FHBG PET Intratumoral injection of sr39tk + T-cells [ 18 F]FHBG PET C. T T T T T T